Invention Grant
- Patent Title: Mutant IDH1 inhibitors
-
Application No.: US16302797Application Date: 2017-05-30
-
Publication No.: US10696665B2Publication Date: 2020-06-30
- Inventor: Wenceslao Lumeras Amador , Serge Louis Boulet , Timothy Paul Burkholder , Santiago Carballares Martin , Raymond Gilmour , Patric James Hahn , Renato Alejandro Bauer , Zoran Rankovic
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Grant E Reed
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@39f665 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@60401e15
- International Application: PCT/US2017/034930 WO 20170530
- International Announcement: WO2017/213910 WO 20171214
- Main IPC: C07D213/04
- IPC: C07D213/04 ; C07D413/14 ; A61K31/506 ; A61P35/00 ; C07D413/04
Abstract:
The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.
Public/Granted literature
- US20190292175A1 MUTANT IDH1 INHIBITORS Public/Granted day:2019-09-26
Information query
